Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Choi, Chang Min ^a   Jang, Se Jin ^a   Park, Seong Yeol ^b   Choi, Yong Bock ^b   Jeong, Jae Heon ^c   Kim, Dae Seok ^b   Kim, Hyun Kyoung ^b   Park, Kang Seo ^b   Nam, Byung Ho ^b   Kim, Hyeong Ryul ^a   Kim, Soo Youl ^b   Hong, Kyeong Man ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; OUTCOME ASSESSMENT; PROGNOSIS; CELL MOTION; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GTP-BINDING PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSGLUTAMINASES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 80053175163     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-119     Document Type: Article

References (22)

1. Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology 2009, 76:239-246. 10.1159/000205386, 19246948.
2. Coate LE, Leighl NB. How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Curr Treat Options Oncol 2011,
3. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263. 10.1634/theoncologist.2008-0232, 19221167.
4. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nature Reviews Molecular Cell Biology 2003, 4:140-156. 10.1038/nrm1014, 12563291.
5. Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 1999, 125:89-95. 10.1007/s004320050247, 10190315.
6. Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 2008, 29:1893-1900. 10.1093/carcin/bgn158, 2556973, 18667446.
7. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. International journal of cancer 1994, 58:400-406.
8. Mehta K, Fok J, Miller FR, Koul D, Sahin A. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clinical cancer research 2004, 10:8068-8076. 10.1158/1078-0432.CCR-04-1107, 15585642.
9. Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:493-502. 10.1007/s00432-009-0681-6, 19763620.
10. Antonyak MA, Li B, Regan AD, Feng Q, Dusaban SS, Cerione RA. Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion. J Biol Chem 2009, 284:17914-17925. 10.1074/jbc.M109.013037, 2709351, 19403524.
11. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008, 68:5849-5858. 10.1158/0008-5472.CAN-07-6130, 2547344, 18632639.
12. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26:2459-2470. 10.1038/sj.onc.1210035, 17043648.
13. Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 2007, 67:7194-7202. 10.1158/0008-5472.CAN-07-0307, 17671187.
14. Chen SH, Lin CY, Lee LT, Chang GD, Lee PP, Hung CC, Kao WT, Tsai PH, Schally AV, Hwang JJ, Lee MT. Up-regulation of fibronectin and tissue transglutaminase promotes cell invasion involving increased association with integrin and MMP expression in A431 cells. Anticancer Res 30:4177-4186.
15. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010, 5:442-447. 10.1097/JTO.0b013e3181d40fac, 20195168.
16. Jeong JM, Murthy SN, Radek JT, Lorand L. The fibronectin-binding domain of transglutaminase. J Biol Chem 1995, 270:5654-5658. 10.1074/jbc.270.10.5654, 7890687.
17. Hang J, Zemskov EA, Lorand L, Belkin AM. Identification of a novel recognition sequence for fibronectin within the NH2-terminal beta-sandwich domain of tissue transglutaminase. J Biol Chem 2005, 280:23675-23683. 10.1074/jbc.M503323200, 15849356.
18. Janiak A, Zemskov EA, Belkin AM. Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. Mol Biol Cell 2006, 17:1606-1619. 10.1091/mbc.E05-06-0549, 1415321, 16452636.
19. Lipscomb EA, Mercurio AM. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev 2005, 24:413-423. 10.1007/s10555-005-5133-4, 16258729.
20. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 2010, 5:e13390. 10.1371/journal.pone.0013390, 2953521, 20967228.
21. Kim D, Park S, Nam B, Kim I, Kim S. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer research 2006, 66:10936-10943. 10.1158/0008-5472.CAN-06-1521, 17108131.
22. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal B, Mehta K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer research 2006, 66:8788-8795. 10.1158/0008-5472.CAN-06-1457, 16951195.